Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how
Open Access
- 9 June 2025
- journal article
- case report
- Published by Elsevier in Clinical Neurology and Neurosurgery
- Vol. 256, 109011
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patientsJournal of Neurology, 2024
- Myasthenic crisisMuscle & Nerve, 2023
- Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case reportJournal of Neurology, 2022
- The use of eculizumab in ventilator‐dependent myasthenia gravis patientsMuscle & Nerve, 2021
- Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19Journal of Neurology, 2021
- ‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumabJournal of Neurology, 2020
- Complement deposition at the neuromuscular junction in seronegative myasthenia gravisActa Neuropathologica, 2020
- Eculizumab in refractory myasthenic crisisMuscle & Nerve, 2018
- Comparative efficacy of low dose, daily versus alternate day plasma exchange in severe myasthenia gravisJournal of Neurology, 2007
- Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptorEuropean Journal of Immunology, 1992